Skip to main content
SpringerLink
Log in

Serum alpha-melanocyte-stimulating hormone (a-MSH), brain-derived neurotrophic factor (BDNF), and agouti-related protein (AGRP) levels in children with Prader-Willi or Bardet-Biedl syndromes

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Although leptin/melanocortin pathway pathologies in hypothalamus are thought to be the main cause of early-onset obesity and hyperphagia in PWS and BBS, the exact mechanism is still not known.

Objective

To measure serum concentrations of a-MSH, BDNF and AGRP in a group of children with BBS or PWS.

Methods

We recruited 12 subjects with PWS, 12 subjects with BBS, 28 obese controls (OC) and 26 lean controls (LC) matched for age, sex and puberty. Serum a-MSH, BDNF and AGRP levels were measured by the ELISA method.

Results

The mean a-MSH level was lower in PWS than those of OC and LC (3729 ± 1319, 5211 ± 829 and 5681 ± 565 pg/ml, respectively, p < 0.001), and mean a-MSH was lower in OC than LC (p < 0.05). The mean BDNF level of PWS was higher than those of OC and LC (565 ± 122, 482 ± 102 and 391 ± 74 pg/ml, respectively, p < 0.001). On the other hand, mean a-MSH level of BBS was lower than those of OC and LC (4543 ± 658, 5211 ± 829 and 5681 ± 565 pg/ml, respectively, p < 0.001), and mean a-MSH was lower in OC than LC (p < 0.05). The mean BDNF level of BBS was higher than those of OC and LC (583 ± 115, 482 ± 102 and 391 ± 74 pg/ml, respectively, p < 0.001). Additionally, both in PWS and BBS, the mean BDNF level was higher in OC than LC (p < 0.01). Regarding AGRP level, there was no difference both in BBS and PWS compared to OC.

Conclusion

We found that the serum a-MSH levels of PWS and BBS groups are significantly lower compared to those of obese and lean controls. Therefore, we can speculate that the circulating a-MSH level does properly reflect its central production, and the serum a-MSH level might be a good biomarker to detect a-MSH deficiency in individuals suspected to have BBS or PWS, and also in those with POMC, PCSK1, and LEPR deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14(1):10–26

    Article  CAS  Google Scholar 

  2. Angulo MA, Butler MG, Cataletto ME (2015) Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 38:1249–1263

    Article  CAS  Google Scholar 

  3. Forsythe E, Beales PL (2013) Bardet-Biedl syndrome. Eur J Hum Genet 21(1):8–13

    Article  CAS  Google Scholar 

  4. Kenny J, Forsythe E, Beales P, Bacchelli C (2017) Toward personalized medicine in Bardet-Biedl syndrome. Per Med 14(5):447–456

    Article  CAS  Google Scholar 

  5. Best S, Lord J, Roche M, Watson CM, Poulter JA, Bevers RPJ, et al. Molecular diagnoses in the congenital malformations caused by ciliopathies cohort of the 100,000 Genomes Project. J Med Genet. 2021; 29: jmedgenet-2021–108065.

  6. Baldini G, Phelan KD (2019) The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol 241:1–33

    Article  Google Scholar 

  7. Ramos-Molina B, Molina-Vega M, Fernández-García JC, Creemers JW. Hyperphagia and Obesity in Prader-Willi Syndrome: PCSK1 Deficiency and Beyond? Genes (Basel). 2018; 7;9(6):288–297.

  8. Feuillan PP, Ng D, Han JC, Sapp JC, Wetsch K, Spaulding E (2011) Patients with Bardet-Biedl syndrome have hyperleptinemia suggestive of leptin resistance. J Clin Endocrinol Metab 96(3):528–535

    Article  Google Scholar 

  9. Han JC, Muehlbauer MJ, Cui HN, Newgard CB, Haqq AM (2010) Lower Brain-Derived Neurotrophic Factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab 95(7):3532–3536

    Article  CAS  Google Scholar 

  10. Bueno M, Esteba-Castillo S, Novell R, Gimenez-Palop O, Coronas R, Gabau E, et al. Lack of postprandial peak in brain-derived neurotrophic factor in adults with Prader- Willi syndrome. PLoS One. 2016; 11(9): e0163468

  11. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA (1999) New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet 36:437–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Neyzi O, Bundak R, Gokcay G, Gunoz H, Furman A, Darendeliler F et al (2015) Reference values for weight, height, head circumference and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7(4):280–293

    Article  Google Scholar 

  13. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44(235):291–303

    Article  CAS  Google Scholar 

  14. Goldstone AP, Holland AJ, Butler JV, Whittington JE (2012) Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obese 36(12):1564–1570

    Article  CAS  Google Scholar 

  15. Butler MG, Moore J, Morawiecki A, Nicolson M (1998) Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet 75:7–12

    Article  CAS  Google Scholar 

  16. Kweh FA, Miller JL, Sulsona CR et al (2015) Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A 167:69–79

    Article  CAS  Google Scholar 

  17. Muscogiuri G, Barrea L, Faggiano F, Maiorino MI, Parrillo M, Pugliese G et al (2021) Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest 44:2057–2070

    Article  CAS  Google Scholar 

  18. Irizarry KA, Miller M, Freemark M, Haqq AM (2016) Prader Willi Syndrome; genetics, metabolomics, hormonal Function, and new approaches to therapy. Adv Pediatr 63(1):47–77

    Article  Google Scholar 

  19. Guo D-F, Lin Z, Yuanming Wu, Searby C, Thedens DR, Richerson GB et al (2019) The BBSome in POMC and AgRP neurons is necessary for body weight regulation and sorting of metabolic receptors. Diabetes 68(8):1591–1603

    Article  CAS  Google Scholar 

  20. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H et al (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 8(12):960–970

    Article  Google Scholar 

  21. Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G et al (2020) Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 22(11):2133–2140

    Article  CAS  Google Scholar 

  22. Poitou C, Mosbah H, Clément K (2020) MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity. Eur J Endocrinol 183(5):149–166

    Article  Google Scholar 

  23. Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR et al (2012) Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med 18:564–571

    Article  CAS  Google Scholar 

  24. Gray J, Yeo GSH, Cox JJ et al (2006) Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF). Gene Diabetes 55:3366–3371

    Article  CAS  Google Scholar 

  25. Yeo GS, Connie Hung CC, Rochford J et al (2004) A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7:1187–1189

    Article  CAS  Google Scholar 

  26. Bochukova EG, Lawler K, Croizier S, Keogh JM, Patel N, Strohbehn G et al (2018) A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader- Willi syndrome. Cell Rep 22(13):3401–3408

    Article  CAS  Google Scholar 

  27. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: Data from the Baltimore longitudinal study of aging. PLoS ONE. 2010; 5: e10099.

  28. Slusher AL, Whitehurst M, Zoeller RF, Mock JT, Maharaj A, Huang CJ (2015) Brain-derived neurotrophic factor and substrate utilization following acute aerobic exercise in obese individuals. J Neuroendocrinol 27:370–376

    Article  CAS  Google Scholar 

  29. Sandrini L, Minno AD, Amadio P, Ieraci A, Tremoli E, Barbieri SS (2018) Association between obesity and circulating brain-derived neurotrophic factor (BDNF) levels: systematic review of literature and meta-analysis. Int J Mol Sc 19:2281

    Article  Google Scholar 

  30. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN et al (2000) Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470(2):113–117

    Article  CAS  Google Scholar 

  31. Amadio P, Baldassarre D, Sandrini L, Weksler BB, Tremoli E, Barbieri SS (2017) Effect of cigarette smoke on monocyte procoagulant activity: Focus on platelet-derived brain-derived neurotrophic factor (BDNF). Platelets 28:60–65

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully thank Dr. Ibrahim Kandemir for statistical analysis, and the study participants for their contribution.

Author information

Authors and Affiliations

  1. Department of Pediatric Endocrinology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey

    D. Turkkahraman

  2. Department of Pediatrics, Antalya Training and Research Hospital, Antalya, Turkey

    E. C. Sirazi

  3. Department of Biochemistry, Antalya Training and Research Hospital, Antalya, Turkey

    G. Aykal

Authors
  1. D. Turkkahraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. C. Sirazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Aykal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design: DT, Data collection or Processing: ECS, Analysis and Interpretation: GA, ECS, Literature Search: ECS, Writing: DT, ECS, GA. All authors critically revised the manuscript and approved the final version.

Corresponding author

Correspondence to D. Turkkahraman.

Ethics declarations

Conflict of interest

The authors state that there is no conflict of interest.

Ethical approval

The study protocol was approved by the local Institutional Review Board (12.09.2019, no: 20/5). The study was conducted according to the principles of the Declaration of Helsinki.

Informed consent

Informed written consents from the subjects (> 8-year-old) and their parents were obtained.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turkkahraman, D., Sirazi, E.C. & Aykal, G. Serum alpha-melanocyte-stimulating hormone (a-MSH), brain-derived neurotrophic factor (BDNF), and agouti-related protein (AGRP) levels in children with Prader-Willi or Bardet-Biedl syndromes. J Endocrinol Invest 45, 1031–1037 (2022). https://doi.org/10.1007/s40618-021-01737-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-021-01737-8

Keywords

Search

Navigation